Latest News About Absi Kick

Here are the latest updates on Absci (ABSI) based on recent public reports:

• ABSI focused on advancing its ABS-201 program for endometriosis, with leadership updates aligning clinical strategy with AI-driven drug design. The company recently announced a new Chief Medical Officer to lead clinical development, and the ABS-201 program is aiming for a Phase 2 start in 2026 with an interim readout in 2027. [Sources reference: multiple 2026 press listings and conference disclosures.]

• In late 2025 and early 2026, Absci participated in investor events and disclosed pipeline progress across several programs, including ABS-101, ABS-301, and ABS-501, as well as partnerships leveraging its AI Drug Creation platform. These updates typically accompany quarterly results and strategic updates. [Sources reference: quarterly results coverage and investor conference mentions.]

• Absci has continued to emphasize partnerships and collaborations to accelerate drug discovery via AI, with announcements around cloud/hardware collaborations and collaborations with universities or research centers to support its platform. [Sources reference: coverage of AI collaboration news and platform updates.]

• Corporate leadership changes in 2026 included the appointment of a new Chief Medical Officer, signaling a shift in clinical leadership to drive the ABS-201 program forward. [Source: leadership announcements from 2026.]

If you’d like, I can pull specific articles or press releases from a particular date range, or summarize a single source in detail. I can also fetch the most current press releases and provide citations.